scholarly journals Comparison of speech and resonance outcomes across three methods of treatment for maxillary defects

2017 ◽  
Vol 1 ◽  
pp. 2-8 ◽  
Author(s):  
Georgina Papadopoulos-Nydam ◽  
Johan Wolfaardt ◽  
Hadi Seikaly ◽  
Dan O'Connell ◽  
Jeffrey Harris ◽  
...  

Purpose: Treatment of maxillary defects, whether by prosthetic rehabilitation or surgical reconstruction, should aim to restore speech function and resonance balance. With the advent of technology and changing clinical practices related to maxillary defect management, speech outcomes need to be evaluated and compared in order to determine efficacy of differing approaches.  Materials and Methods: One hundred and four patients across three treatment groups for maxillary defects were included: 38 patients who were treated with maxillary obturators (OBT group), 39 patients who were treated with a standard fibular free flap reconstruction that did not involve digital planning of the reconstruction (Standard group) and 27 patients who were reconstructed using a digitally planned surgical design and simulation fibular free flap reconstruction (SDS group). Speech assessments were completed to assess word and sentence intelligibility, resonance balance and aeromechanical orifice estimation among these three groups. Assessments included the Computerized Assessment of Intelligibility of Dysarthric Speech (C-AIDS), nasalance scores via the Nasometer and palatopharyngeal orifice area via the PERCI-SARS. Results: Significant differences were found in word intelligibility between the SDS and the Standard groups (p =.035) and on nasalance scores between the SDS and the OBT groups (p=.027). Conclusions: Patients treated with digital reconstruction (SDS) had better speech outcomes than the other two treatment groups, whose mean scores on certain speech variables were not within normal limits. Speech outcomes in the SDS group were consistently within the normal range across all measured speech variables.

Head & Neck ◽  
2021 ◽  
Author(s):  
C. Burton Wood ◽  
Austin Y. Ha ◽  
Sidharth V. Puram ◽  
Ryan S. Jackson ◽  
Patrik Pipkorn

2017 ◽  
Vol 33 (04) ◽  
pp. 281-291 ◽  
Author(s):  
Thomas Mücke ◽  
Andreas Fichter ◽  
Florian Güll ◽  
Christopher Schmid ◽  
Jean Duc ◽  
...  

2017 ◽  
Vol 45 (1) ◽  
pp. 113-119 ◽  
Author(s):  
Lucas M. Ritschl ◽  
Thomas Mücke ◽  
Andreas M. Fichter ◽  
Maximilian Roth ◽  
Clemens Kaltenhauser ◽  
...  

2020 ◽  
Author(s):  
Yun Liu ◽  
Xi Zhu ◽  
Dan Zhou ◽  
Fang Han ◽  
Xu Dong Yang

Abstract Background: Postoperative pulmonary complications (PPCs) are common and significant problems for oral and maxillofacial surgery patients. Dexmedetomidine (DEX), an α2-adrenoreceptor agonist, has been proven having lung protection effects. However, since now, there has not been final conclusion about whether DEX can reduce the incidence of PPCs. We hypothesize that, in oral and maxillofacial surgery with fibular free flap reconstruction patients, DEX may decrease the incidence of PPCs.Methods: This was a prospective, double-blind, randomized, placebo-controlled, single-centered trial with two parallel arms. A total of 160 patients at intermediate-to-high risk of PPCs undergoing oral and maxillofacial surgery with fibular free flap reconstruction and tracheotomy were enrolled and randomized to receive continuous infusion of either DEX or placebo (normal saline). 0.4 ug/kg of DEX was given over 10mins as an initial dose followed by a maintaining dose of 0.4 ug/kg/h till the second day morning after surgery. At the same time, the normal saline was administered a similar quantity. The primary outcome was the incidence of PPCs according to Clavien-Dindo score within 7 days after surgery. Results: The two groups had similar characteristics at baseline. 18(22.5%) of 80 patients administered DEX, and 32(40.0%) of 80 patient administered placebo experienced PPCs within the first 7 days after surgery (relative risk [RR] 0.563,95% confidence interval [CI] 0.346-0.916; P=0.017). In the first 7 days after surgery, the DEX group had a lower incidence of PPCs and a better postoperative survival probability (Log-rank test, P=0.019), and was less prone to occur PPCs (Cox regression, P=0.025, HR=0.516). When the total dose of DEX was more than 328μg, the patients were unlikely to have PPCs (ROC curve, AUC=0.614, P=0.009).Conclusions: For patients undergoing oral and maxillofacial surgery with fibular free flap reconstruction and tracheotomy who were at intermediate or high risk of developing PPCs, continuous infusion of DEX could decrease the occurrence of PPCs during the first 7 days after surgery and shorten the length of hospital stay after surgery, but did not increase the prevalence of bradycardia or hypotension. Trial registration: Chinese Clinical Trial Registry, www.chictr.org.cn, number: ChiCTR1800016153; Registered on May 15, 2018.


Sign in / Sign up

Export Citation Format

Share Document